**Background**
The renin-angiotensin system (RAS) plays a critical role in the regulation of blood pressure and fluid balance. Within this system, the angiotensin II type 1 (AT1) receptor is a primary mediator of the vasoconstrictive and pro-inflammatory effects of angiotensin II. Overactivation of the AT1 receptor is closely linked to the development of hypertension and chronic kidney diseases, particularly diabetic nephropathy. In diabetic conditions, the activation of the angiotensin II/p38/SIRT1 pathway can induce podocyte apoptosis, leading to increased albuminuria and progressive renal failure. Consequently, targeting the AT1 receptor has become a cornerstone in the pharmacological management of renal protection and blood pressure control. In this context, we will introduce a potent and selective AT1 receptor blocker – Olmesartan medoxomil.
**Definition**
Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with an IC50 value of 66.2 μM.
**In Vitro and In Vivo Studies**
The Olmesartan medoxomil biological activity has been extensively evaluated across various models. In vitro studies demonstrate that Olmesartan medoxomil inhibits the metabolism of arachidonic acid (AA) in a concentration-dependent manner, with an IC50 of 66.2 μM. Additionally, research into its antiviral potential showed that in Vero E6 cells, Olmesartan exhibited an EC50 > 40 μM against the SARS-CoV-2 strain BavPat1, as measured by the inhibition of viral RNA replication via RT-PCR after 2 days.
Regarding Olmesartan medoxomil in vivo efficacy, studies were conducted using db/db diabetic mice. These mice typically exhibit an 11.7-fold increase in albuminuria compared to control mice by week 22 to 24 of age. Administration of Olmesartan (20 mg/kg) for 12 weeks (starting from week 10 to 12 of age) significantly reduced albuminuria by 77% compared to placebo-treated db/db mice. Furthermore, the albumin/creatinine ratio (ACR), which is increased 7.1-fold in db/db mice relative to controls, was significantly decreased by 59% following Olmesartan treatment. These results suggest that the compound prevents microalbuminuria by inhibiting podocyte apoptosis. For researchers seeking detailed Olmesartan medoxomil technical information, these findings highlight its potential in treating diabetic kidney complications. In conclusion, Olmesartan medoxomil is a potent AT1 receptor blocker that provides significant renal protection in diabetic models.
Keywords
Olmesartan medoxomil, 144689-63-4, CS 866, CS866, CS-866, Angiotensin Receptor, Inhibitor, inhibitor, inhibit
References
[1] Senda A, et al. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8. Biol Pharm Bull. 2015;38(12):1975-9.
[2] Shah S, et al. Simultaneous Quantitative Analysis of Olmesartan Medoxomil and Amlodipine Besylate in Plasma by High-performance Liquid Chromatography Technique.
J Young Pharm. 2012 Apr;4(2):88-94.
[3] Gu J, et al. Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis. Kidney Blood Press Res. 2016 Nov 21;41(6):848-864.